Gyroscope partners with UPenn for gene therapies targeting eye disease

By The Science Advisory Board staff writers

December 18, 2020 -- Gyroscope Therapeutics has entered into a sponsored research agreement with the University of Pennsylvania (UPenn) and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases.

Together, CAROT and Gyroscope researchers will explore specific gene therapy targets for glaucoma, optic neuritis, and retinitis pigmentosa. Gyroscope has an exclusive option to the intellectual property derived from the research conducted under the agreement.

Gyroscope's lead investigational gene therapy is being evaluated in phase II clinical trials for the treatment of geographic atrophy secondary to dry age-related macular degeneration, a leading cause of blindness.

Financial details of the agreement were not disclosed.

Janssen acquires rights to AMD gene therapy
Janssen Pharmaceuticals has acquired rights of Hemera Biosciences' investigational gene therapy, HMR59, a one-time, outpatient, intravitreal injection...
AGTC touts positive early clinical results for gene therapy
Applied Genetic Technologies (AGTC) has reported positive data from its ongoing phase I/II clinical trial evaluating its adeno-associated virus (AAV)-based...
Novartis acquires Vedere Bio
Novartis has acquired Vedere Bio in a deal that includes that company's lead preclinical intravitreally injected adeno-associated virus gene therapy program,...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter